

Effects of senescence and angiotensin II on expression and processing of amyloid precursor protein in human cerebral microvascular endothelial cells

Ruohan Sun^{1,2}, Tongrong He², Yujun Pan¹, Zvonimir S. Katusic²

¹Department of Neurology, the First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, 150001, China

²Department of Anesthesiology and Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA

Correspondence to: Yujun Pan, Zvonimir S. Katusic; **email:** yujunpan@ems.hrbmu.edu.cn; katusic.zvonimir@mayo.edu

Keywords: APP processing, endothelium, senescence, Ang II, BACE1 inhibitor IV

Received: September 15, 2017 **Accepted:** January 10, 2018

Published: January 15, 2018

Copyright: Sun et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

The present study was designed to determine the effects of senescence and angiotensin II (Ang II) on expression and processing of amyloid precursor protein (APP) in human brain microvascular endothelial cells (BMECs). Senescence caused a decrease in APP expression thereby resulting in reduced secretion of soluble APP α (sAPP α). In contrast, β -site APP cleaving enzyme (BACE1) expression and production of amyloid β (A β)₄₀ were increased in senescent endothelium. Importantly, in senescent human BMECs, treatment with BACE1 inhibitor IV inhibited A β generation and increased sAPP α production by enhancing a disintegrin and metalloprotease (ADAM)10 expression. Furthermore, Ang II impaired expression of ADAM10 and significantly reduced generation of sAPP α in senescent human BMECs. This inhibitory effect of Ang II was prevented by treatment with BACE1 inhibitor IV. Our results suggest that impairment of α -processing and shift to amyloidogenic pathway of APP contribute to endothelial dysfunction induced by senescence. Loss of sAPP α in senescent cells treated with Ang II exacerbates detrimental effects of senescence on APP processing. Notably, inhibition of BACE1 has beneficial effects on senescence induced endothelial dysfunction. Reported findings may help to explain contributions of senescent cerebral microvascular endothelium to development of cerebral amyloid angiopathy and Alzheimer's disease (AD) pathology.

INTRODUCTION

Epidemiological, experimental and clinical studies have suggested that age-related cerebrovascular dysfunction plays a critical role in the pathogenesis of dementia, including Alzheimer's disease (AD) [1-4]. The amyloid cascade hypothesis remains the most frequently invoked hypothesis to explain the pathogenesis of AD [5]. Amyloid β (A β), the main constituent of amyloid plaques and a key pathogenic factor in AD, has detrimental effects on cerebral blood vessels resulting in

disruption of homeostatic function of the cerebrovascular endothelial cells [6-8].

Cellular senescence is an important contributor to aging and age-related diseases [9-12]. Prior studies provided evidence that processing of endogenous amyloid precursor protein (APP) is down-regulated in senescent human fibroblasts [13], but the effects of senescence on APP expression and processing in vascular endothelium have not been studied. APP is highly expressed in

endothelium and can be processed by two major proteolytic pathways [14]. In the non-amyloidogenic pathway, APP is cleaved by α -secretase within the A β sequence thereby generating soluble APP α (sAPP α), a well-known anticoagulant, neurotrophic, and neuro-protective molecule [14-16]. In contrast, amyloidogenic processing of APP sequentially driven by β -site APP cleaving enzyme (BACE1) and γ -secretase generates cytotoxic A β [14]. Under physiological conditions, endothelial APP is primarily processed via non-amyloidogenic pathway [14, 17]. A disintegrin and metalloprotease (ADAM)10 has been identified as the major α -secretase responsible for processing of APP [18]. Our previous studies demonstrated that in human brain microvascular endothelial cells (BMECs), ADAM10 is stimulated by activation of prostacyclin (PGI₂)/cyclic adenosine monophosphate (cAMP) signaling pathway [16]. On the other hand, we also have demonstrated that the expression and activity of BACE1 in cerebrovascular endothelium is suppressed by endothelial nitric oxide synthase (eNOS)/nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) signaling [19]. The inhibition of β -secretase by NO and stimulation of α -secretase by PGI₂ contribute to predominant cleavage of APP via α -secretase pathway in endothelium. Under pathological conditions, β -processing of APP is activated therefore increasing production of A β [14, 17]. Importantly, inhibition of BACE1 could prevent or reduce the accumulation of A β in the brain, thereby reducing AD-related pathology [20-22]. Not surprisingly, inhibitors of BACE1 are currently being developed for the treatment of AD [21, 23, 24]. However, the effects of BACE1 inhibitors on human brain microvascular endothelium have not been defined.

Hypertension is one of the vascular risk factors implicated in the pathogenesis of AD. Indeed, midlife hypertension increases the risk for development of AD later in life [25, 26]. Multiple lines of experimental evidence suggest that hypertension-induced cerebral microvascular impairment precedes cognitive decline [2, 27, 28] and AD neuropathology [29-32]. However, the molecular mechanisms responsible for hypertension-induced alterations in vascular function contributing to the development of AD are poorly characterized. Angiotensin II (Ang II) is a candidate for the hypothesized mechanistic link between hypertension and AD [33]. Prior studies established that vasoconstrictor and pro-oxidant effects of Ang II contribute to pathogenesis of essential hypertension [34, 35]. Furthermore, increased circulating levels of Ang II accelerate development of AD pathology by promoting β -secretase activity [32, 36]. Existing literature supports the concept that Ang II increases superoxide production by activation of angiotensin II type 1 receptor (AT₁R) in cerebral microvascular endothelium thereby causing

endothelial dysfunction [37-40]. However, no previous study has assessed the direct effects of Ang II on metabolism of APP in endothelial cells of human brain blood vessels. Therefore, in this study, we determined the effects of Ang II on APP expression and its metabolism in young and senescent human brain microvascular endothelium.

RESULTS

Levels of APP expression and processing of APP in human BMECs during cellular senescence

Human BMECs were sequentially passaged and the senescent cells showed substantially slower growth rates, increasing expression of the senescence marker p16^{INK4a} and more cells positive for senescence-associated β -galactosidase (SA- β -Gal) activity (Figure 1A-D). To determine the effects of senescence on expression of APP and its metabolism in human BMECs, we examined the protein levels of APP, α - and β -secretases. APP protein levels were significantly reduced in the senescent human BMECs (Figure 2A). We assessed the expression of ADAM10, ADAM9 and ADAM17, since these three metalloproteases of the ADAM family have been suggested to exert α -secretase activity in metabolism of APP [41]. ADAM10 (but not ADAM9 or ADAM17) appears to be a major contributor to both constitutive and inducible α -secretase activity in endothelial cells [14, 16, 42]. We found that the expression of ADAM10 and ADAM17 were not changed (Figure 2B-C), however, senescence increased the expression of ADAM9 in passage 15 (P15) human BMECs (Figure 2D). Although there was no decrease in α -secretase expression, the secretion of sAPP α was surprisingly lower in senescent human BMECs (Figure 2E).

We next investigated senescence-associated alterations in amyloidogenic processing of APP. Western blot analysis detected a significant up-regulation of BACE1 (Figure 2F). Consistent with increased BACE1, levels of A β 40 were significantly increased in senescent human BMECs (Figure 2G). The production of A β 42 was undetectable (n=13, data not shown). Schematic summary of effects of senescence on expression and processing of APP is shown in Figure 6A.

Effects of β -secretase inhibitor IV (BACE1 inhibitor IV) on APP expression and processing in young and senescent human BMECs

We next determined the effects of BACE1 inhibitor IV on APP expression and its metabolism. Treatment with BACE1 inhibitor IV resulted in decrease of A β 40 production both in young and senescent human BMECs

(Figure 3A and Figure 3D, respectively). Surprisingly, BACE1 inhibitor IV caused significant increase in expression of ADAM10 (Figure 3B and Figure 3E). In senescent cells treated with BACE1 inhibitor IV, sAPP α levels were significantly up-regulated (Figure 3F). BACE1 inhibitor IV did not affect sAPP α production in young cells (Figure 3C). We further studied expressions of APP, ADAM9 and ADAM17 but no alterations of these protein levels were observed in cells treated with BACE1 inhibitor IV (Supplementary Figure 1A-F). Schematic summary of APP expression and processing in human senescent BMECs treated with BACE1 inhibitor IV is shown in Figure 6B.

Effects of Ang II on APP expression and processing in young and senescent human BMECs

First, treatment of young human BMECs with increasing concentrations (0.5nM and 1nM) of Ang II for 24h did not change protein levels of APP and ADAM10 (Supplementary Figure 2A-B). While Ang II caused an increase in expression of BACE1 (Supplementary Figure 2C), levels of A β 40 were unchanged

(Supplementary Figure 2D, A β 42 production was undetectable, n=11, data not shown). Inhibition of angiotensin II type 2 receptor (AT₂R) by PD123319 (but not AT₁R inhibition by losartan), blocked the stimulatory effect of Ang II on expression of BACE1 (Supplementary Figure 2E). Moreover, treatment with nuclear factor κ B (NF- κ B) inhibitor, PDTC, rather than protein kinase C (PKC) inhibitor, Ro-31-8220, reversed Ang II-induced enhancement of BACE1 protein expression (Supplementary Figure 2F). We next determined the effects of Ang II on senescent human BMECs. Interestingly, ADAM10 protein levels were significantly reduced (Figure 4A). This effect was abolished by AT₂R antagonist PD123319 (but not AT₁R antagonist losartan; Figure 4B). More importantly, production of sAPP α was statistically lower following Ang II treatment (Figure 4C). No changes in APP or BACE1 expression were seen in senescent cells treated with Ang II (Figure 4D-E). Since BACE1 inhibitor IV increased ADAM10 expression and sAPP α production in senescent cells, we tested the possibility that BACE1 inhibitor IV reverses the impaired expression of ADAM10 and production of sAPP α caused by Ang II treatment.




Figure 1. Senescence of human BMECs. (A) Growth curves of P5 and P15 human BMECs, n=3, *P<0.05, compared to P5 on the same day. (B) Expression of senescence-associated marker p16^{INK4a} in human BMECs, n=9. (C) Staining of young and senescent human BMECs for SA- β -Gal (left) and the percentage of β -gal positive cells (right), n=6. Data are presented as mean \pm SEM, *P<0.05, compared to P5.




Figure 2. The influence of senescence on expression and processing of APP in human BMECs. Human BMECs were passaged 5 and 15 times. Cell lysates were subjected to Western blot. Protein levels of (A) APP, (B) ADAM10, (C) ADAM17, (D) ADAM9 and (F) BACE1 were measured, n=6-9. Cells were incubated in 1.5ml EGM2 for 24h. Conditioned media were collected for measuring sAPPα (E, n=13) and Aβ40 (G, n=15) via commercially available ELISA kits respectively. Data are presented as mean±SEM, *P<0.05, compared to P5.

Our data showed that BACE1 inhibitor IV significantly elevated ADAM10 expression in cells treated with Ang II (Figure 5A), however it did not recover reduced sAPPα caused by Ang II (Figure 5B). Interestingly, the protein levels of APP were significantly decreased in cells treated with Ang II plus BACE1 inhibitor IV (Figure 5C). Schematic summaries of effects of Ang II or Ang II combined with BACE1 inhibitor IV on α-processing of APP in senescent cells are shown in Figure 6C and Figure 6D.

DISCUSSION

In the present study, we report several novel findings. First, senescence impairs the expression of APP in human BMECs. Although cellular senescence does not

decrease α-secretase expression, the production of sAPPα is significantly reduced, most likely as a result of decreased expression of APP protein. Second, BACE1 protein levels are elevated in senescent human BMECs. Consistent with increased BACE1, production of Aβ40 is significantly up-regulated. Third, both in young and senescent human BMECs, treatment with BACE1 inhibitor IV reduces Aβ generation and increases ADAM10 levels. However, production of sAPPα is only elevated in senescent BMECs. Fourth, AT₂R/NF-κB signaling is involved in Ang II-induced enhancement of BACE1 expression in young endothelial cells. In contrast, Ang II suppresses ADAM10 protein levels by activation of AT₂R thereby decreasing sAPPα production in senescent cells. These observations suggest that in endothelium AT₂R is responsible

for the effects of Ang II on APP metabolism. Senescent human BMECs are more sensitive to inhibitory effect of Ang II on α -processing of APP, and that loss of sAPP α caused by Ang II may impair the function of senescent human cerebrovascular endothelium. Finally, BACE1 inhibitor IV reverses decreased ADAM10 expression caused by Ang II, thereby restoring normal expression of ADAM10.

Vascular aging is characterized by endothelial dysfunction, thickened intima-media layer, enlarged vascular lumen, increased vascular stiffness, predisposition to development of atherosclerosis, decreased angiogenesis and aberrant response to stimuli [43, 44]. Senescent endothelial cells have several major functional abnormalities, such as loss of replicative potential and increased susceptibility to injury [43]. Although the exact molecular mechanisms linking endothelial senescence with vascular aging are poorly understood, existing evidence suggests that senescent

endothelial cells significantly contribute to age-related vascular disease [43, 45, 46].

Previous studies have demonstrated that APP is highly expressed in vascular endothelium and that intraluminal release of the APP cleavage products may play an important role in vascular homeostasis [14, 16, 47]. In the present study, passaging of cultured human BMECs resulted in senescence, including slower growth rates and increased expression of p16^{INK4a} and SA- β -Gal activity. Most notably, our studies are the first to demonstrate that in senescent human brain microvascular endothelium, the progressive decrease in sAPP α is associated with a reduced expression of APP. While we do not have an exact explanation for the decreased APP levels, it was shown that age-associated decreased maturation of APP in human fibroblasts was directly affected by increased level of intracellular cholesterol [13]. Of note, the expression of ADAM10 is unchanged and ADAM9 is increased in senescent




Figure 3. The effects of BACE1 inhibitor IV on young and senescent human BMECs. P5 cells (A and C) and P15 cells (D and F) were treated with 2ml EGM2 + BACE1 inhibitor IV (5μM) or 2ml EGM2 alone (ctrl) for 24h. Aβ40 (A and D, n=6-7) and sAPPα (C and F, n=6) levels from cell supernatants were analyzed using commercially available ELISA kits respectively. P5 cells (B) and P15 cells (E) were treated with BACE1 inhibitor IV with indicated concentrations for 24h. Protein samples were subjected to Western blot, n=4. Data are presented as mean±SEM, *P<0.05, compared to control.

endothelium. The mechanisms of APP processing by ADAM9 are not fully understood [42, 48]. Controversial observations have been reported, demonstrating that there is an association between ADAM9 and activity of ADAM10 [49-51], however, the exact effect of increased expression of ADAM9 on ADAM10 protease activity in senescent endothelial cells remains to be determined.

In neuronal tissue, inadequate sAPP α levels may be sufficient to polarize APP processing toward the amyloidogenic pathway [52, 53]. Consistent with this concept, in senescent human BMECs, loss of sAPP α is associated with significant increase in BACE1 expression and A β 40 levels. Existing evidence indicates that deposition of A β exerts detrimental effects on cerebral blood vessels and impairs endothelial structure and function [54-56]. Since BACE1 is the rate limiting enzyme in the production of A β , BACE1 inhibitors have emerged as an attractive therapeutic approach in

prevention and treatment of AD [21, 57, 58]. Because α - and β -secretase appear to compete for the intracellular pool of APP, sAPP α is increased upon BACE1 inhibition in neuronal cells [20, 59]. In our studies, as expected, BACE1 inhibitor IV significantly decreased the generation of A β 40 both in young and senescent human BMECs. However, we wish to emphasize that our findings are the first to demonstrate that BACE1 inhibitor IV increased sAPP α levels by elevating ADAM10 expression in senescent human brain microvascular endothelium. Currently, we do not have an explanation as to why increased expression of ADAM10 did not result in increased production of sAPP α in young endothelial cells in response to BACE1 inhibitor IV. Nevertheless, our findings suggest that BACE1 inhibitors may exert beneficial effects in senescent human BMECs by shifting APP processing to α -pathway. Further studies will be needed to determine the exact mechanism responsible for elevated ADAM10 expression caused by BACE1 inhibitors.




Figure 4. Ang II impairs α -processing of APP in senescent human BMECs. Cells were treated with Ang II with indicated concentrations for 24h. Cell lysates were collected for Western blot. Protein expression of (A) ADAM10, (D) APP and (E) BACE1 were measured, n=6-7. (C) Cell supernatants (1.5ml) were collected for sAPP α detection via a commercially available ELISA kit, n=11. *P<0.05, compared to control. (B) Senescent cells were treated with losartan (1 μ M) or PD123319 (1 μ M) for 1h, and then incubated with Ang II (0.5nM) for 24h. ADAM10 expression was measured, n=10. *P<0.05, compared to Ang II (0.5nM), #P<0.05, compared to Ang II (0.5nM) plus losartan (1 μ M). Data are presented as mean \pm SEM.




Figure 5. The effects of BACE1 inhibitor IV on α -processing of APP in senescent human BMECs treated with Ang II. Senescent BMECs were treated with Ang II (1nM) alone or Ang II (1nM) plus BACE1 inhibitor IV (5 μ M) for 24h. Protein samples were subject to Western blot. Protein levels of (A) ADAM10 and (C) APP were detected, n=6-7. (B) Conditioned media (5ml) were collected for measuring sAPP α via the ELISA kit, n=8. Data are presented as mean \pm SEM, *P<0.05, compared to Ang II (1nM) alone.

In the present study, we also examined the effects of Ang II on expression and processing of APP in young and senescent human BMECs. Based on the circulating levels of Ang II detected in patients with hypertension, 0.5nM and 1nM concentrations of Ang II were used [60, 61]. Both AT₁R and AT₂R protein are expressed in cultured human cerebral microvascular endothelium [62, 63]. AT₁R has been shown to mediate majority of the physiological and pathological actions of Ang II [64]. The effects mediated by activation of AT₂R in endothelial cells are not completely understood [65, 66]. Interestingly, our findings demonstrate that in young human BMECs Ang II increased the expression of BACE1 by activation of AT₂R. Existing evidence suggests that transcription factor NF- κ B plays a role in regulation of BACE1 protein expression [67]. Furthermore, in rat glomerular endothelial cells Ang II activates NF- κ B by AT₂R-dependent signaling [68]. Of note, existing literature suggests that activation of PKC

could also up-regulate BACE1 protein levels in endothelial cells [69]. In our experiments, treatment with NF- κ B inhibitor, PDTC, (but not PKC inhibitor, Ro-31-8220), attenuated Ang II-induced up-regulation of BACE1 expression. This observation implies that NF- κ B signaling is involved in Ang II-induced enhancement of BACE1 expression. Although the expression of BACE1 was increased, we still did not observe any changes in production and release of A β peptides. The exact mechanisms responsible for the discrepancy between increased expression of BACE1 and unchanged A β levels are currently unknown and remain to be determined. Interestingly, in senescent human BMECs, Ang II did not increase expression of BACE1. It is possible that because the levels of BACE1 protein have already been elevated in senescent human BMECs, treatment with Ang II could not further increase expression of BACE1. However, Ang II decreased ADAM10 protein levels in senescent endothelium.




Figure 6. Schematic summary of effects of senescence, Ang II and BACE1 inhibitor IV on expression and processing of APP in human BMECs. (A) and (B) Senescence impairs α -processing of APP and enhances β -processing of APP. BACE1 inhibitor IV reverses the impairment caused by senescence by inhibiting $A\beta$ generation and increasing expression of ADAM10 and sAPP α production. (C) and (D) Ang II impairs α -processing of APP in senescent cells. BACE1 inhibitor IV reverses reduced ADAM10 expression caused by Ang II, but does not affect sAPP α production, most likely as a result of decreased expression of APP. [\uparrow = up-regulation, \downarrow =down-regulation, (-)=no effect].

This effect was also dependent on activation of AT₂R. Besides decreased ADAM10, Ang II also significantly reduced sAPP α generation in senescent endothelium. It is important to note that no previous study has characterized the effects of sAPP α on cerebrovascular endothelium. However, recent studies suggest that in neuronal cells, sAPP α exerts inhibitory effect on β -processing of APP [52, 53]. Therefore, reduced sAPP α production by endothelium might impair the balance between non-amyloidogenic and amyloidogenic processing of APP. The impairment of α -processing and potential shift to β -processing of APP may help to explain dysfunction of senescent endothelium in response to Ang II. Moreover, endothelium-derived sAPP α contains KPI domain that has anticoagulation function responsible for protection against thrombosis in cerebral circulation [14, 70]. More importantly, our recent studies have demonstrated that sAPP α production in cerebral endothelial cells affects levels of sAPP α in the hippocampus [16, 71]. Since sAPP α is a well-known neuroprotective and neurotrophic molecule [14], cerebral endothelium-derived sAPP α may significantly contribute to protection of hippocampal function. Therefore our findings indicate that in the senescent endothelium loss of sAPP α induced by Ang II may increase vulnerability of vascular and neuronal cells to

injury. Finally, we wish to point out that in order to prevent decreased ADAM10 expression and sAPP α levels caused by Ang II, senescent endothelial cells were treated with a combination of Ang II and BACE1 inhibitor IV. We observed a significant increase in ADAM10 expression during combined treatment. However, the levels of sAPP α were not recovered, most likely as a result of decreased expression of APP.

Taken together, the results of the present study suggest that reduced APP expression contributes to down-regulation of sAPP α in senescent brain microvascular endothelium. Increased BACE1 expression and $A\beta$ production suggest that senescence promotes β -processing of APP. Treatment with BACE1 inhibitor IV is beneficial for senescent human BMECs. This effect is mediated by shifting of APP processing towards non-amyloidogenic pathway. The present study also reports a novel observation regarding the detrimental effects of Ang II on α -processing of APP by activation of AT₂R in senescent human BMECs. Given the fact that the cleavage products of APP play an important role in vascular homeostasis, we propose that increased $A\beta$ production together with loss of sAPP α are previously unrecognized mechanisms of cerebral microvascular endothelial dysfunction induced by senescence and Ang

II. Our findings support the concept that pathological expression and processing of APP in senescent cerebrovascular endothelium may play an important role in pathogenesis of cerebral amyloid angiopathy and AD.

METHODS

Cell culture

Primary human BMECs were purchased from Applied Cell Biology Research Institute (Kirkland, WA). Human BMECs were grown in endothelial growth medium 2 (EGM2; Lonza, Allendale, NJ) which contained: endothelial basal medium 2 (EBM2; Lonza, Allendale, NJ) supplemented with 2% fetal bovine serum, fibroblast growth factor, vascular endothelial growth factor, insulin-like growth factor, epidermal growth factor, ascorbic acid, hydrocortisone, bac off and heparin.

Senescence of cells was induced by serial passages [13, 72]. Cells were regarded as young at passage 5 (P5) and senescent at passage 15 (P15) [72]. We generated growth curves using P5 and P15 human BMECs by counting cell number every 24h for 5 days. At day 0, we plated 2.5×10^4 human BMECs per 100mm dish and changed media every day [73].

In some experiments, human BMECs were treated with or without increasing concentrations of BACE1 inhibitor IV (0.1 μ M, 0.5 μ M, 5 μ M) (Calbiochem, Billerica, MA) [57] or human Ang II (0.5nM, 1nM) (Sigma Aldrich, St. Louis, MO) [60, 61] for 24h. For Ang II receptor/pathway blockade, human BMECs were treated with AT₁R antagonist, losartan (1 μ M) (Cayman, Ann Arbor, MI) [68], or AT₂R antagonist, PD123319 (1 μ M) (Cayman, Ann Arbor, MI) [68], or NF- κ B inhibitor, PDTC (50 μ M) (Calbiochem, Billerica, MA) [74], or PKC inhibitor, Ro-31-8220 (1 μ M) (Calbiochem, Billerica, MA) [69, 75] for 1h prior to Ang II treatment.

Senescence-associated β -Galactosidase staining (SA- β -Gal)

We stained P5 and P15 human BMECs for SA- β -Gal activity according to manufacturer's protocol (BioVision, Milpitas, CA). The percentage of senescent cells was calculated by the total number of senescent cells (blue color) divided by the total number of cells counted under a microscope (Nikon Eclipse TE2000-U Microscope, 150x total magnification) [73].

Western blot analysis

To perform Western blot analysis, cells were collected and lysed in ice cold lysis buffer [10mM HEPES,

50mM NaF, 50mM NaCl, 5mM EDTA, 5mM EGTA, 100 μ M Na₃VO₄, 50mM Na pyrophosphate, 1% Triton X-100, pH 7.4, and protease inhibitor cocktail (Sigma, St. Louis, MO)] as previously described [16]. Equal protein amounts were resolved by SDS-PAGE and transferred to nitrocellulose membranes. Blots were probed with APP (Invitrogen, Carlsbad, CA), BACE1 (Abcam, Cambridge, MA), ADAM10, ADAM17 (Millipore, Billerica, MA), ADAM9 (Cell Signaling, Danvers, MA), p16^{INK4a} (Cell Applications, San Diego, CA) and β -actin (Sigma Aldrich, St. Louis, MO) specific primary antibodies. Protein expression was normalized to β -actin. For α -secretase, the protein levels of mature ADAM10, mature ADAM9, and mature ADAM17 (lower bands on the blots) were quantified.

ELISA for sAPP α , A β 40, and A β 42

Secreted sAPP α , A β 40, and A β 42 from cell supernatant were measured using human sAPP α high sensitive assay kit (Immuno-Biological Laboratories-America, Minneapolis, MN), human A β 40 ELISA kit, and human A β 42 ELISA kit (Invitrogen, Camarillo, CA), respectively, following manufacturer's protocols.

Statistical analysis

Data are presented as mean \pm SEM. Differences between mean values of multiple groups were analyzed using one-way ANOVA followed by Tukey test (SigmaStat 12.0 for Windows). The growth curves of different passages were compared on individual days. Unpaired Student *t*-test was used to analyze comparison between two groups. *P*<0.05 was considered statistically significant.

Abbreviations

A β : amyloid β ; AD: Alzheimer's disease; ADAM: a disintegrin and metalloprotease; Ang II: angiotensin II; APP: amyloid precursor protein; AT₁R: angiotensin II type 1 receptor; AT₂R: angiotensin II type 2 receptor; BACE1: β -site APP cleaving enzyme 1; BACE1 inhibitor IV: β -secretase inhibitor IV; BMECs: brain microvascular endothelial cells; cAMP: cyclic adenosine monophosphate; cGMP: cyclic guanosine monophosphate; EBM2: endothelial basal medium 2; EGM2: endothelial growth medium 2; eNOS: endothelial nitric oxide synthase; NF- κ B: nuclear factor κ B; NO: nitric oxide; P5: passage 5; P15: passage 15; PGI₂: prostacyclin; PKC: protein kinase C; SA- β -Gal: senescence-associated β -galactosidase; sAPP α : soluble APP α .

AUTHOR CONTRIBUTIONS

Ruohan Sun: experimental design, data collection and analysis, and manuscript writing. Tongrong He: experi-

mental design and manuscript writing. Yujun Pan: manuscript writing. Zvonimir S. Katusic: experimental design and manuscript writing.

CONFLICTS OF INTEREST

The authors have no conflicts of interest to declare.

FUNDING

The authors would like to acknowledge following funding sources: National Institutes of Health (NIH) Grants HL-111062, HL-131515 and the Mayo Foundation.

REFERENCES

1. Ighodaro ET, Abner EL, Fardo DW, Lin AL, Katsumata Y, Schmitt FA, Kryscio RJ, Jicha GA, Neltner JH, Monsell SE, Kukull WA, Moser DK, Appiah F, et al, and Alzheimer's Disease Neuroimaging Initiative (ADNI). Risk factors and global cognitive status related to brain arteriosclerosis in elderly individuals. *J Cereb Blood Flow Metab.* 2017; 37:201–16. <https://doi.org/10.1177/0271678X15621574>
2. Toth P, Tarantini S, Csiszar A, Ungvari Z. Functional vascular contributions to cognitive impairment and dementia: mechanisms and consequences of cerebral autoregulatory dysfunction, endothelial impairment, and neurovascular uncoupling in aging. *Am J Physiol Heart Circ Physiol.* 2017; 312:H1–20. <https://doi.org/10.1152/ajpheart.00581.2016>
3. Cooper LL, Woodard T, Sigurdsson S, van Buchem MA, Torjesen AA, Inker LA, Aspelund T, Eiriksdottir G, Harris TB, Gudnason V, Launer LJ, Mitchell GF. Cerebrovascular Damage Mediates Relations Between Aortic Stiffness and Memory. *Hypertension.* 2016; 67:176–82. <https://doi.org/10.1161/HYPERTENSIONAHA.115.06398>
4. Lourenço CF, Ledo A, Barbosa RM, Laranjinha J. Neurovascular uncoupling in the triple transgenic model of Alzheimer's disease: impaired cerebral blood flow response to neuronal-derived nitric oxide signaling. *Exp Neurol.* 2017; 291:36–43. <https://doi.org/10.1016/j.expneurol.2017.01.013>
5. Aisen PS, Cummings J, Jack CR Jr, Morris JC, Sperling R, Frölich L, Jones RW, Dowsett SA, Matthews BR, Raskin J, Scheltens P, Dubois B. On the path to 2025: understanding the Alzheimer's disease continuum. *Alzheimers Res Ther.* 2017; 9:60. <https://doi.org/10.1186/s13195-017-0283-5>
6. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. *Nat Rev Neurosci.* 2011; 12:723–38. <https://doi.org/10.1038/nrn3114>
7. Hamel E. Cerebral circulation: function and dysfunction in Alzheimer's disease. *J Cardiovasc Pharmacol.* 2015; 65:317–24. <https://doi.org/10.1097/FJC.000000000000177>
8. Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. *Nat Rev Neurosci.* 2017; 18:419–34. <https://doi.org/10.1038/nrn.2017.48>
9. Erusalimsky JD, Kurz DJ. Cellular senescence in vivo: its relevance in ageing and cardiovascular disease. *Exp Gerontol.* 2005; 40:634–42. <https://doi.org/10.1016/j.exger.2005.04.010>
10. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. *Cell.* 2013; 153:1194–217. <https://doi.org/10.1016/j.cell.2013.05.039>
11. Naylor RM, Baker DJ, van Deursen JM. Senescent cells: a novel therapeutic target for aging and age-related diseases. *Clin Pharmacol Ther.* 2013; 93:105–16. <https://doi.org/10.1038/clpt.2012.193>
12. Childs BG, Gluscevic M, Baker DJ, Laberge RM, Marquess D, Dananberg J, van Deursen JM. Senescent cells: an emerging target for diseases of ageing. *Nat Rev Drug Discov.* 2017; 16:718–35. <https://doi.org/10.1038/nrd.2017.116>
13. Kern A, Roempp B, Prager K, Walter J, Behl C. Down-regulation of endogenous amyloid precursor protein processing due to cellular aging. *J Biol Chem.* 2006; 281:2405–13. <https://doi.org/10.1074/jbc.M505625200>
14. d'Uscio LV, He T, Katusic ZS. Expression and Processing of Amyloid Precursor Protein in Vascular Endothelium. *Physiology (Bethesda).* 2017; 32:20–32. <https://doi.org/10.1152/physiol.00021.2016>
15. Kögel D, Deller T, Behl C. Roles of amyloid precursor protein family members in neuroprotection, stress signaling and aging. *Exp Brain Res.* 2012; 217:471–79. <https://doi.org/10.1007/s00221-011-2932-4>
16. He T, Santhanam AV, Lu T, d'Uscio LV, Katusic ZS. Role of prostacyclin signaling in endothelial production of soluble amyloid precursor protein- α in cerebral microvessels. *J Cereb Blood Flow Metab.* 2017; 37:106–22. <https://doi.org/10.1177/0271678X15618977>
17. Chow VW, Mattson MP, Wong PC, Gleichmann M. An overview of APP processing enzymes and products. *Neuromolecular Med.* 2010; 12:1–12.


<https://doi.org/10.1007/s12017-009-8104-z>

18. Endres K, Deller T. Regulation of Alpha-Secretase ADAM10 In vitro and In vivo: Genetic, Epigenetic, and Protein-Based Mechanisms. *Front Mol Neurosci*. 2017; 10:56. <https://doi.org/10.3389/fnmol.2017.00056>
19. Austin SA, Santhanam AV, Hinton DJ, Choi DS, Katusic ZS. Endothelial nitric oxide deficiency promotes Alzheimer's disease pathology. *J Neurochem*. 2013; 127:691–700. <https://doi.org/10.1111/jnc.12334>
20. Nishitomi K, Sakaguchi G, Horikoshi Y, Gray AJ, Maeda M, Hirata-Fukae C, Becker AG, Hosono M, Sakaguchi I, Minami SS, Nakajima Y, Li HF, Takeyama C, et al. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice. *J Neurochem*. 2006; 99:1555–63. <https://doi.org/10.1111/j.1471-4159.2006.04178.x>
21. Vassar R. BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. *Alzheimers Res Ther*. 2014; 6:89. <https://doi.org/10.1186/s13195-014-0089-7>
22. Ben Halima S, Mishra S, Raja KM, Willem M, Baici A, Simons K, Brüstle O, Koch P, Haass C, Cafilisch A, Rajendran L. Specific Inhibition of β -Secretase Processing of the Alzheimer Disease Amyloid Precursor Protein. *Cell Reports*. 2016; 14:2127–41. <https://doi.org/10.1016/j.celrep.2016.01.076>
23. Menting KW, Claassen JA. β -secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease. *Front Aging Neurosci*. 2014; 6:165. <https://doi.org/10.3389/fnagi.2014.00165>
24. Yan R, Vassar R. Targeting the β secretase BACE1 for Alzheimer's disease therapy. *Lancet Neurol*. 2014; 13:319–29. [https://doi.org/10.1016/S1474-4422\(13\)70276-X](https://doi.org/10.1016/S1474-4422(13)70276-X)
25. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, et al, and American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2011; 42:2672–713. <https://doi.org/10.1161/STR.0b013e3182299496>
26. Faraco G, Iadecola C. Hypertension: a harbinger of stroke and dementia. *Hypertension*. 2013; 62:810–17. <https://doi.org/10.1161/HYPERTENSIONAHA.113.01063>
27. Capone C, Faraco G, Park L, Cao X, Davisson RL, Iadecola C. The cerebrovascular dysfunction induced by slow pressor doses of angiotensin II precedes the development of hypertension. *Am J Physiol Heart Circ Physiol*. 2011; 300:H397–407. <https://doi.org/10.1152/ajpheart.00679.2010>
28. Toth P, Tucsek Z, Sosnowska D, Gautam T, Mitschelen M, Tarantini S, Deak F, Koller A, Sonntag WE, Csiszar A, Ungvari Z. Age-related autoregulatory dysfunction and cerebrovascular injury in mice with angiotensin II-induced hypertension. *J Cereb Blood Flow Metab*. 2013; 33:1732–42. <https://doi.org/10.1038/jcbfm.2013.143>
29. Carnevale D, Lembo G. 'Alzheimer-like' pathology in a murine model of arterial hypertension. *Biochem Soc Trans*. 2011; 39:939–44. <https://doi.org/10.1042/BST0390939>
30. Carnevale D, Mascio G, Ajmone-Cat MA, D'Andrea I, Cifelli G, Madonna M, Coccozza G, Frati A, Carullo P, Carnevale L, Alleva E, Branchi I, Lembo G, Minghetti L. Role of neuroinflammation in hypertension-induced brain amyloid pathology. *Neurobiol Aging*. 2012; 33:205.e19–29. <https://doi.org/10.1016/j.neurobiolaging.2010.08.013>
31. Carnevale D, Mascio G, D'Andrea I, Fardella V, Bell RD, Branchi I, Pallante F, Zlokovic B, Yan SS, Lembo G. Hypertension induces brain β -amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. *Hypertension*. 2012; 60:188–97. <https://doi.org/10.1161/HYPERTENSIONAHA.112.195511>
32. Cifuentes D, Poittevin M, Dere E, Broquères-You D, Bonnin P, Benessiano J, Pocard M, Mariani J, Kubis N, Merkulova-Rainon T, Lévy BI. Hypertension accelerates the progression of Alzheimer-like pathology in a mouse model of the disease. *Hypertension*. 2015; 65:218–24. <https://doi.org/10.1161/HYPERTENSIONAHA.114.04139>
33. Kehoe PG, Miners S, Love S. Angiotensins in Alzheimer's disease - friend or foe? *Trends Neurosci*. 2009; 32:619–28. <https://doi.org/10.1016/j.tins.2009.07.006>
34. Coffman TM. Under pressure: the search for the essential mechanisms of hypertension. *Nat Med*. 2011; 17:1402–09. <https://doi.org/10.1038/nm.2541>
35. Reudelhuber TL. Where hypertension happens. *J Clin Invest*. 2013; 123:1934–36. <https://doi.org/10.1172/JCI69296>


36. Faraco G, Park L, Zhou P, Luo W, Paul SM, Anrather J, Iadecola C. Hypertension enhances A β -induced neurovascular dysfunction, promotes β -secretase activity, and leads to amyloidogenic processing of APP. *J Cereb Blood Flow Metab.* 2016; 36:241–52. <https://doi.org/10.1038/jcbfm.2015.79>
37. Girouard H, Park L, Anrather J, Zhou P, Iadecola C. Angiotensin II attenuates endothelium-dependent responses in the cerebral microcirculation through Nox-2-derived radicals. *Arterioscler Thromb Vasc Biol.* 2006; 26:826–32. <https://doi.org/10.1161/01.ATV.0000205849.22807.6e>
38. Chrissobolis S, Banfi B, Sobey CG, Faraci FM. Role of Nox isoforms in angiotensin II-induced oxidative stress and endothelial dysfunction in brain. *J Appl Physiol (1985).* 2012; 113:184–91. <https://doi.org/10.1152/jappphysiol.00455.2012>
39. Kazama K, Anrather J, Zhou P, Girouard H, Frys K, Milner TA, Iadecola C. Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. *Circ Res.* 2004; 95:1019–26. <https://doi.org/10.1161/01.RES.0000148637.85595.c5>
40. Xiao X, Zhang C, Ma X, Miao H, Wang J, Liu L, Chen S, Zeng R, Chen Y, Bihl JC. Angiotensin-(1-7) counteracts angiotensin II-induced dysfunction in cerebral endothelial cells via modulating Nox2/ROS and PI3K/NO pathways. *Exp Cell Res.* 2015; 336:58–65. <https://doi.org/10.1016/j.yexcr.2015.06.010>
41. Vingtdoux V, Marambaud P. Identification and biology of α -secretase. *J Neurochem.* 2012 (Suppl 1); 120:34–45. <https://doi.org/10.1111/j.1471-4159.2011.07477.x>
42. Kuhn PH, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart JW, Kremmer E, Rossner S, Lichtenthaler SF. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. *EMBO J.* 2010; 29:3020–32. <https://doi.org/10.1038/emboj.2010.167>
43. Tian XL, Li Y. Endothelial cell senescence and age-related vascular diseases. *J Genet Genomics.* 2014; 41:485–95. <https://doi.org/10.1016/j.jgg.2014.08.001>
44. Yang T, Sun Y, Lu Z, Leak RK, Zhang F. The impact of cerebrovascular aging on vascular cognitive impairment and dementia. *Ageing Res Rev.* 2017; 34:15–29. <https://doi.org/10.1016/j.arr.2016.09.007>
45. LeBrasseur NK, Tchkonina T, Kirkland JL. Cellular Senescence and the Biology of Aging, Disease, and Frailty. *Nestle Nutr Inst Workshop Ser.* 2015; 83:11–18. <https://doi.org/10.1159/000382054>
46. Minamino T, Komuro I. Vascular aging: insights from studies on cellular senescence, stem cell aging, and progeroid syndromes. *Nat Clin Pract Cardiovasc Med.* 2008; 5:637–48. <https://doi.org/10.1038/ncpcardio1324>
47. Canobbio I, Abubaker AA, Visconte C, Torti M, Pula G. Role of amyloid peptides in vascular dysfunction and platelet dysregulation in Alzheimer's disease. *Front Cell Neurosci.* 2015; 9:65. <https://doi.org/10.3389/fncel.2015.00065>
48. Marolda R, Ciotti MT, Matrone C, Possenti R, Calissano P, Cavallaro S, Severini C. Substance P activates ADAM9 mRNA expression and induces α -secretase-mediated amyloid precursor protein cleavage. *Neuropharmacology.* 2012; 62:1954–63. <https://doi.org/10.1016/j.neuropharm.2011.12.025>
49. Tousseyn T, Thathiah A, Jorissen E, Raemaekers T, Konietzko U, Reiss K, Maes E, Snellinx A, Serneels L, Nyabi O, Annaert W, Saftig P, Hartmann D, De Strooper B. ADAM10, the rate-limiting protease of regulated intramembrane proteolysis of Notch and other proteins, is processed by ADAMS-9, ADAMS-15, and the gamma-secretase. *J Biol Chem.* 2009; 284:11738–47. <https://doi.org/10.1074/jbc.M805894200>
50. Moss ML, Powell G, Miller MA, Edwards L, Qi B, Sang QX, De Strooper B, Tesseur I, Lichtenthaler SF, Taverna M, Zhong JL, Dingwall C, Ferdous T, et al. ADAM9 inhibition increases membrane activity of ADAM10 and controls α -secretase processing of amyloid precursor protein. *J Biol Chem.* 2011; 286:40443–51. <https://doi.org/10.1074/jbc.M111.280495>
51. Cissé MA, Sunyach C, Lefranc-Jullien S, Postina R, Vincent B, Checler F. The disintegrin ADAM9 indirectly contributes to the physiological processing of cellular prion by modulating ADAM10 activity. *J Biol Chem.* 2005; 280:40624–31. <https://doi.org/10.1074/jbc.M506069200>
52. Obregon D, Hou H, Deng J, Giunta B, Tian J, Darlington D, Shahaduzzaman M, Zhu Y, Mori T, Mattson MP, Tan J. Soluble amyloid precursor protein- α modulates β -secretase activity and amyloid- β generation. *Nat Commun.* 2012; 3:777. <https://doi.org/10.1038/ncomms1781>
53. Peters-Libeau C, Campagna J, Mitsumori M, Poksay KS, Spilman P, Sabogal A, Bredesen DE, John V. sA β PP α is a Potent Endogenous Inhibitor of BACE1. *J Alzheimers Dis.* 2015; 47:545–55. <https://doi.org/10.3233/JAD-150282>
54. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. *Nat Rev Neurosci.* 2004; 5:347–60. <https://doi.org/10.1038/nrn1387>

55. Katusic ZS, Austin SA. Endothelial nitric oxide: protector of a healthy mind. *Eur Heart J*. 2014; 35:888–94. <https://doi.org/10.1093/eurheartj/ehf544>
56. Koizumi K, Wang G, Park L. Endothelial Dysfunction and Amyloid- β -Induced Neurovascular Alterations. *Cell Mol Neurobiol*. 2016; 36:155–65. <https://doi.org/10.1007/s10571-015-0256-9>
57. Cai J, Qi X, Kociok N, Skosyrski S, Emilio A, Ruan Q, Han S, Liu L, Chen Z, Bowes Rickman C, Golde T, Grant MB, Saftig P, et al. β -Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. *EMBO Mol Med*. 2012; 4:980–91. <https://doi.org/10.1002/emmm.201101084>
58. Weber M, Wu T, Meilandt WJ, Dominguez SL, Solanoy HO, Maloney JA, Ngu H, Baca M, Kung C, Lima L, Earr TK, Fleck D, Shields SD, et al. BACE1 across species: a comparison of the in vivo consequences of BACE1 deletion in mice and rats. *Sci Rep*. 2017; 7:44249. <https://doi.org/10.1038/srep44249>
59. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. *Science*. 1999; 286:735–41. <https://doi.org/10.1126/science.286.5440.735>
60. Catt KJ, Cain MD, Zimmet PZ, Cran E. Blood angiotensin II levels of normal and hypertensive subjects. *BMJ*. 1969; 1:819–21. <https://doi.org/10.1136/bmj.1.5647.819>
61. Catt KJ, Cran E, Zimmet PZ, Best JB, Cain MD, Coghlan JP. Angiotensin II blood-levels in human hypertension. *Lancet*. 1971; 1:459–64. [https://doi.org/10.1016/S0140-6736\(71\)91085-3](https://doi.org/10.1016/S0140-6736(71)91085-3)
62. Krishnan S, Shanmuganathan MV, Behenna D, Stoltz BM, Prasadarao NV. Angiotensin II receptor type 1—a novel target for preventing neonatal meningitis in mice by *Escherichia coli* K1. *J Infect Dis*. 2014; 209:409–19. <https://doi.org/10.1093/infdis/jit499>
63. Alhusban A, Kozak A, Ergul A, Fagan SC. AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator. *J Pharmacol Exp Ther*. 2013; 344:348–59. <https://doi.org/10.1124/jpet.112.197483>
64. Timmermans PB, Smith RD. Angiotensin II receptor subtypes: selective antagonists and functional correlates. *Eur Heart J*. 1994 (Suppl D); 15:79–87. https://doi.org/10.1093/eurheartj/15.suppl_D.79
65. Pueyo ME, Michel JB. Angiotensin II receptors in endothelial cells. *Gen Pharmacol*. 1997; 29:691–96. [https://doi.org/10.1016/S0306-3623\(97\)00021-9](https://doi.org/10.1016/S0306-3623(97)00021-9)
66. Chow BS, Allen TJ. Angiotensin II type 2 receptor (AT2R) in renal and cardiovascular disease. *Clin Sci (Lond)*. 2016; 130:1307–26. <https://doi.org/10.1042/CS20160243>
67. Tamagno E, Guglielmotto M, Monteleone D, Vercelli A, Tabaton M. Transcriptional and post-transcriptional regulation of β -secretase. *IUBMB Life*. 2012; 64:943–50. <https://doi.org/10.1002/iub.1099>
68. Wolf G, Wenzel U, Burns KD, Harris RC, Stahl RA, Thaiss F. Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors. *Kidney Int*. 2002; 61:1986–95. <https://doi.org/10.1046/j.1523-1755.2002.00365.x>
69. Deng X, Zhang J, Liu Y, Chen L, Yu C. TNF- α regulates the proteolytic degradation of ST6Gal-1 and endothelial cell-cell junctions through upregulating expression of BACE1. *Sci Rep*. 2017; 7:40256. <https://doi.org/10.1038/srep40256>
70. Xu F, Davis J, Miao J, Previti ML, Romanov G, Ziegler K, Van Nostrand WE. Protease nexin-2/amyloid beta-protein precursor limits cerebral thrombosis. *Proc Natl Acad Sci USA*. 2005; 102:18135–40. <https://doi.org/10.1073/pnas.0507798102>
71. He T, Sun R, Santhanam AV, d'Uscio LV, Lu T, Katusic ZS. Impairment of amyloid precursor protein alpha-processing in cerebral microvessels of type 1 diabetic mice. *J Cereb Blood Flow Metab*. 2017; 37:1774–81. <https://doi.org/10.1007/s12274-017-0698-1>
72. Bianchessi V, Vinci MC, Nigro P, Rizzi V, Farina F, Capogrossi MC, Pompilio G, Gualdi V, Lauri A. Methylation profiling by bisulfite sequencing analysis of the mtDNA Non-Coding Region in replicative and senescent Endothelial Cells. *Mitochondrion*. 2016; 27:40–47. <https://doi.org/10.1016/j.mito.2016.02.004>
73. Baker DJ, Jeganathan KB, Cameron JD, Thompson M, Juneja S, Kopecka A, Kumar R, Jenkins RB, de Groen PC, Roche P, van Deursen JM. BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. *Nat Genet*. 2004; 36:744–49. <https://doi.org/10.1038/ng1382>
74. He T, Katusic ZS. Brain-derived neurotrophic factor increases expression of MnSOD in human circulating angiogenic cells. *Microvasc Res*. 2012; 83:366–71. <https://doi.org/10.1016/j.mvr.2012.01.001>
75. Wang L, Shim H, Xie C, Cai H. Activation of protein kinase C modulates BACE1-mediated beta-secretase activity. *Neurobiol Aging*. 2008; 29:357–67. <https://doi.org/10.1016/j.neurobiolaging.2006.11.001>

SUPPLEMENTARY MATERIAL



Supplementary Figure 1. APP, ADAM9 and ADAM17 protein levels were unchanged by BACE1 inhibitor IV treatment of young and senescent human BMECs. P5 cells (A, B and C) and P15 cells (D, E and F) were treated with BACE1 inhibitor IV with indicated concentrations for 24h. Cell lysates were subjected to Western blot. Protein levels of APP (A and D, n=5), ADAM9 (B and E, n=3) and ADAM17 (C and F, n=3) were measured. Data are presented as mean±SEM.



Supplementary Figure 2. The effects of Ang II on expression and processing of APP in young human BMECs. P5 cells were treated with Ang II with indicated concentrations for 24h. Cell lysates were subjected to Western blot. Protein levels of (A) APP, n=7-9, (B) ADAM10, n=7-9 and (C) BACE1, n=9-14 were measured. *P<0.05, compared to control. (D) BMECs were cultured in the absence or presence of 1nM Ang II for 24h. Conditioned media (2ml) were collect for measuring Aβ40 via a commercially available ELISA kit, n=11. (E) Cells were treated with losartan (10^{-6} M) or PD123319 (10^{-6} M) for 1h, and then incubated with Ang II (1nM) for 24h. BACE1 expression was measured, n=7. *P<0.05, compared to Ang II (1nM), #P<0.05, compared to Ang II (1nM) plus losartan (10^{-6} M). (F) Cells were treated with PDTC (50μM) or Ro-31-8220 (1μM) for 1h, and then incubated with Ang II (1nM) for 24h. BACE1 expression was measured, n=6. *P<0.05, compared to control, #P<0.05, compared to Ang II (1nM) plus PDTC (50μM). Data are presented as mean±SEM.